<?xml version="1.0" encoding="UTF-8"?><abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>http://api.elsevier.com/content/abstract/scopus_id/84901439182</prism:url><dc:identifier>SCOPUS_ID:84901439182</dc:identifier><eid>2-s2.0-84901439182</eid><pubmed-id>24853463</pubmed-id><prism:doi>10.1016/j.ijpharm.2014.05.023</prism:doi><dc:title>PH-Responsive poly(itaconic acid-co-N-vinylpyrrolidone) hydrogels with reduced ionic strength loading solutions offer improved oral delivery potential for high isoelectric point-exhibiting therapeutic proteins</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><citedby-count>4</citedby-count><prism:publicationName>International Journal of Pharmaceutics</prism:publicationName><dc:publisher>Elsevier</dc:publisher><source-id>22454</source-id><prism:issn>18733476</prism:issn><prism:volume>471</prism:volume><prism:issueIdentifier>1-2</prism:issueIdentifier><prism:startingPage>83</prism:startingPage><prism:endingPage>91</prism:endingPage><prism:pageRange>83-91</prism:pageRange><prism:coverDate>2014-08-25</prism:coverDate><dc:creator><author auid="56180413500" seq="1"><ce:initials>M.C.</ce:initials><ce:indexed-name>Koetting M.C.</ce:indexed-name><ce:surname>Koetting</ce:surname><ce:given-name>Michael C.</ce:given-name><preferred-name><ce:initials>M.C.</ce:initials><ce:indexed-name>Koetting M.</ce:indexed-name><ce:surname>Koetting</ce:surname><ce:given-name>Michael C.</ce:given-name></preferred-name><author-url>http://api.elsevier.com/content/author/author_id/56180413500</author-url><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60013372" id="60013372"/></author></dc:creator><dc:description><abstract original="y" xml:lang="eng"><ce:para>pH-Responsive hydrogels comprised of itaconic acid copolymerized with N-vinylpyrrolidone (P(IA-co-NVP)) were synthesized and tested as carriers for the oral delivery of high isoelectric point (pI) exhibiting therapeutic proteins. Swelling studies show that P(IA-co-NVP) hydrogels exhibit significantly greater and faster pH-responsive swelling than previously studied methacrylic acid-based hydrogels, achieving up to 68% greater equilibrium swelling and 10.4 times greater swelling in time-limited experiments. Using salmon calcitonin as a model high pI protein therapeutic, we show that P(IA-co-NVP) hydrogels exhibit significantly greater delivery potential than methacrylic acid-based hydrogels. Additionally, we show that utilizing a lower ionic strength solution during drug loading significantly improves drug delivery potential for high pI therapeutics. By using a 1.5 mM PBS buffer rather than the standard 150 mM PBS buffer during loading, up to 83 times as much calcitonin can be delivered in neutral conditions, with up to a 9.6-fold improvement in percent release. Using P(IA-co-NVP) hydrogel microparticles and a low ionic strength loading solution, up to 48 μg calcitonin/mg hydrogel can be delivered in small intestinal conditions. Based on expected absorption in the small intestine, this is sufficient delivery potential for achieving therapeutic dosage via a single, regularly-sized pill taken daily. © 2014 Elsevier B.V.</ce:para></abstract></dc:description><link href="http://api.elsevier.com/content/abstract/scopus_id/84901439182" rel="self"/><link href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84901439182&amp;origin=inward" rel="scopus"/><link href="http://api.elsevier.com/content/search/scopus?query=refeid%282-s2.0-84901439182%29" rel="cited-by"/></coredata><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60013372" id="60013372"><affilname>University of Texas at Austin</affilname></affiliation><authors><author auid="56180413500" seq="1"><ce:initials>M.C.</ce:initials><ce:indexed-name>Koetting M.C.</ce:indexed-name><ce:surname>Koetting</ce:surname><ce:given-name>Michael C.</ce:given-name><preferred-name><ce:initials>M.C.</ce:initials><ce:indexed-name>Koetting M.</ce:indexed-name><ce:surname>Koetting</ce:surname><ce:given-name>Michael C.</ce:given-name></preferred-name><author-url>http://api.elsevier.com/content/author/author_id/56180413500</author-url><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60013372" id="60013372"/></author><author auid="36042831900" seq="2"><ce:initials>N.A.</ce:initials><ce:indexed-name>Peppas N.A.</ce:indexed-name><ce:surname>Peppas</ce:surname><ce:given-name>Nicholas A.</ce:given-name><preferred-name><ce:initials>N.A.</ce:initials><ce:indexed-name>Peppas N.</ce:indexed-name><ce:surname>Peppas</ce:surname><ce:given-name>Nicholas A.</ce:given-name></preferred-name><author-url>http://api.elsevier.com/content/author/author_id/36042831900</author-url><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60013372" id="60013372"/><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60013372" id="60013372"/><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60013372" id="60013372"/></author></authors></abstracts-retrieval-response>
